Want to see HK:1093 full AI Analyst Report?
Top Page
CSPC Pharmaceutical Group
(1093)
Select Model
Select Model
Rating:80Outperform
Price Target:
HK$11.00
▲(15.55% Upside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by strong financial quality—especially the very low leverage balance sheet and resilient profitability—supported by reasonable valuation (P/E ~12.56 and ~3.05% yield). Technicals are constructive with the price above key moving averages and neutral-to-positive momentum, though the overall score is moderated by recent revenue softness and margin compression versus earlier years.
Positive Factors
Very Low Leverage
Extremely low leverage gives CSPC substantial financial flexibility to fund research, manufacturing capacity and commercialization without heavy interest or refinancing burdens, supporting resilience through changing pharmaceutical demand and regulatory conditions.
Negative Factors
Weak Recent Revenue Growth
Recent revenue performance shows limited momentum after prior declines, raising questions about the pace of portfolio adoption and market expansion. Sustained low growth could constrain operating leverage and reduce resources available for innovation.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Extremely low leverage gives CSPC substantial financial flexibility to fund research, manufacturing capacity and commercialization without heavy interest or refinancing burdens, supporting resilience through changing pharmaceutical demand and regulatory conditions.
Read all positive factors
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$104.68B
Dividend Yield3.31%
Average Volume (3M)97.06M
Price to Earnings (P/E)11.5
Beta (1Y)0.84
Revenue Growth25.21%
EPS Growth103.93%
CountryHK
Employees18,626
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.65
Shares Outstanding11,522,452,000
10 Day Avg. Volume98,645,383
30 Day Avg. Volume97,063,843
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)2.90
Price to Sales (P/S)3.80
P/FCF Ratio24.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.16Price Target Upside38.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)0.75
Revenue Forecast (FY)HK$32.72B
CSPC Pharmaceutical Group Business Overview & Revenue Model
Company Description
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic o...
How the Company Makes Money
CSPC Pharmaceutical Group makes money primarily by selling pharmaceutical products and related services through its operating subsidiaries. Its core revenue model is product-based: (1) Sales of finished pharmaceutical products: The company generat...
CSPC Pharmaceutical Group Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.86B | 25.33B | 29.54B | 31.47B | 31.59B | 27.41B |
| Gross Profit | 22.17B | 16.62B | 20.67B | 22.19B | 22.73B | 20.79B |
| EBITDA | 9.98B | 5.24B | 7.18B | 8.59B | 8.85B | 7.57B |
| Net Income | 7.32B | 3.78B | 4.41B | 5.88B | 6.22B | 5.51B |
Balance Sheet | ||||||
| Total Assets | 56.01B | 46.72B | 44.36B | 46.28B | 41.18B | 34.68B |
| Cash, Cash Equivalents and Short-Term Investments | 18.48B | 8.87B | 7.75B | 13.09B | 13.87B | 10.73B |
| Total Debt | 652.37M | 641.38M | 507.33M | 706.90M | 582.54M | 93.87M |
| Total Liabilities | 16.59B | 12.15B | 10.52B | 11.26B | 10.06B | 7.91B |
| Stockholders Equity | 37.62B | 33.19B | 32.24B | 33.20B | 29.77B | 25.94B |
Cash Flow | ||||||
| Free Cash Flow | 2.00B | 3.99B | 1.74B | 2.29B | 6.62B | 2.88B |
| Operating Cash Flow | 2.76B | 5.90B | 4.26B | 4.18B | 8.10B | 4.64B |
| Investing Cash Flow | -1.94B | -4.13B | -4.41B | 607.27M | -7.19B | -637.33M |
| Financing Cash Flow | -2.32B | -2.44B | -5.11B | -2.30B | -1.95B | -2.20B |
CSPC Pharmaceutical Group Technical Analysis
Neutral
9.52
Price Trends
8.71
Positive
8.12
Positive
8.45
Positive
Market Momentum
0.23
Positive
49.87
Neutral
52.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1093, the sentiment is Neutral. The current price of 9.52 is above the 20-day moving average (MA) of 9.26, above the 50-day MA of 8.71, and above the 200-day MA of 8.45, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 49.87 is Neutral, neither overbought nor oversold. The STOCH value of 52.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1093.
CSPC Pharmaceutical Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | HK$104.68B | 11.55 | 20.68% | 3.31% | 25.21% | 103.93% | |
68 Neutral | HK$28.05B | 5.73 | 7.92% | 5.57% | 7.94% | 52.83% | |
63 Neutral | HK$99.90B | 35.27 | 7.56% | 2.19% | 14.57% | -31.09% | |
61 Neutral | HK$27.27B | 15.02 | 8.60% | 3.16% | 14.80% | -2.88% | |
61 Neutral | HK$64.31B | 12.64 | 6.21% | 4.82% | 8.02% | -17.74% | |
59 Neutral | HK$36.18B | 12.58 | 6.64% | 6.43% | 6.58% | -4.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1093
CSPC Pharmaceutical Group
8.77
-0.98
-10.03%
HK:1177
Sino Biopharmaceutical
5.48
-2.76
-33.47%
HK:0867
China Medical System Holdings
10.88
-3.64
-25.09%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
13.43
-4.01
-22.98%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.15
-0.59
-5.00%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.30
-0.41
-8.78%
CSPC Pharmaceutical Group Corporate Events
CSPC Pharmaceutical Profit More Than Doubles on Finished Drug Growth
Aug 20, 2026
CSPC Pharmaceutical Group reported strong interim results for the six months ended 30 June 2026, driven mainly by robust growth in its finished drugs segment. Group revenue rose 40.1% year-on-year to RMB18.59 billion, while reported profit attribu...
CSPC Pharmaceutical Declares Interim Dividend for First Half of 2026
Aug 20, 2026
CSPC Pharmaceutical Group Limited has declared an interim ordinary cash dividend of HKD 0.18 per share for the six months ended 30 June 2026, payable in Hong Kong dollars. The ex-dividend date is set for 20 October 2026, with the record date on 26...
CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Drug for Liver Cancer in China
Aug 19, 2026
CSPC Pharmaceutical Group has officially initiated a Phase Ib/II clinical trial of SYS6090 Injection, a Class 1 therapeutic biological product, at the first centre in China for the treatment of hepatocellular carcinoma. SYS6090 is a recombinant fu...
CSPC Seeks Priority Approval in China for Novel HER2-Positive Breast Cancer Regimen
Aug 18, 2026
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted, under a priority review procedure, a new drug application for the combination of Anbenitamab (KN026) and its albumin-bound docetaxel (HB1...
CSPC Innovation Posts Strong Interim Turnaround With Tripled Revenue and Robust Profit
Aug 17, 2026
CSPC Pharmaceutical Group’s Shenzhen‑listed subsidiary, CSPC Innovation Pharmaceutical, released unaudited interim results for the six months ended 30 June 2026 showing a sharp turnaround to profitability. Revenue surged 208.72% year o...
CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme
Aug 12, 2026
CSPC Pharmaceutical Group Limited has announced a change in the trustee for its 2018 Share Award Scheme, a restricted share-based incentive plan for selected participants. With effect from 12 August 2026, BOCI Trustee (Hong Kong) Limited will repl...
CSPC Receives US$30 Million Upfront Payment from AstraZeneca for siRNA Collaboration
Aug 12, 2026
CSPC Pharmaceutical Group has received an upfront payment of US$30 million from AstraZeneca under their recently signed collaboration, option and license agreement. The funding follows the July 2026 deal to jointly develop novel small nucleic acid...
CSPC Launches First-in-Class CAR-T Trial for Refractory Lupus in China
Aug 11, 2026
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYS6063, a chimeric antigen receptor T-cell therapy designed to treat relapsed, refractory systemic lupus erythematosus. SYS6063 is described as the first CAR-T product ...
CSPC Pharmaceutical Sets Board Meeting to Approve Interim Results
Aug 10, 2026
CSPC Pharmaceutical Group Limited has scheduled a board meeting for 20 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The announcement signals an upcoming disclosure of the company’s mi...
CSPC Wins U.S. FDA Nod for Clinical Trials of Novel Mpox mRNA Vaccine
Aug 10, 2026
CSPC Pharmaceutical Group has secured approval from the U.S. Food and Drug Administration to begin clinical trials of SYS6037, an mRNA-based mpox vaccine co-developed with the Institute of Microbiology of the Chinese Academy of Sciences. The vacci...
CSPC Pharmaceutical Group Secures US$10 Million Milestone From AstraZeneca
Aug 5, 2026
CSPC Pharmaceutical Group has received a US$10 million milestone payment from AstraZeneca under their strategic research collaboration, following AstraZeneca’s exercise of a license option for one of CSPC’s pre-clinical candidate progr...
CSPC and AstraZeneca Form Biologics Manufacturing Joint Venture in China
Aug 5, 2026
CSPC Pharmaceutical Group has signed a joint venture contract with AstraZeneca to build a new-generation biologics manufacturing facility in Shijiazhuang, China. CSPC will hold 51 percent and AstraZeneca 49 percent of the venture, which initially ...
CSPC Drug Combo for HER2-Positive Breast Cancer Wins Priority NMPA Review
Aug 4, 2026
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted, under priority review, a new drug application for Anbenitamab (KN026) combined with its self-developed albumin-bound docetaxel (HB1801) f...
CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Therapy for Colorectal Cancer in China
Aug 3, 2026
CSPC Pharmaceutical Group has initiated a Phase Ib/II clinical trial in China for SYS 6090 Injection, a Class 1 therapeutic biological product designed as a recombinant fully human PD-1 and IL-15 fusion protein for colorectal cancer. The therapy a...
CSPC Wins China Trial Nod for New RSV Vaccine Targeting Seniors
Jul 31, 2026
CSPC Pharmaceutical Group announced that its recombinant respiratory syncytial virus vaccine, SYS6057, has received approval from China’s National Medical Products Administration to begin clinical trials. The vaccine uses an RSV prefusion F ...
CSPC Launches Phase II Trial of Novel Ovarian Cancer Therapy in China
Jul 31, 2026
CSPC Pharmaceutical Group has begun a Phase II clinical trial in China for SYS6041, an antibody-drug conjugate designed as a combination therapy for recurrent ovarian cancer. The drug targets folate receptor alpha, delivering a topoisomerase I inh...
CSPC Pharmaceutical Uses FX Contracts to Manage USD/RMB Risk
Jul 30, 2026
CSPC Pharmaceutical Group, through wholly owned unit CSPC Zhongqi, has entered into an FX swap and two FX forward contracts with Industrial and Commercial Bank of China to manage its USD/RMB currency exposure. The transactions, funded with interna...
CSPC Launches Phase II Trial for Innovative siRNA Hypertension Drug in China
Jul 29, 2026
CSPC Pharmaceutical Group Limited is a Hong Kong-based pharma developer with significant operations in China’s prescription drug market, focusing on innovative treatments for chronic conditions. Its portfolio is expanding into next-generatio...
CSPC-Linked Cancer Drug Wins FDA Nod for Registrational Trial in U.S.
Jul 29, 2026
CSPC Pharmaceutical Group announced that its licensed drug candidate CRB-701 (SYS6002), a next-generation antibody-drug conjugate developed by Corbus Pharmaceuticals, has received U.S. FDA clearance to begin a registrational trial for second-line ...
CSPC’s Novel Antidepressant HA1406 Hits Phase III Trial Target
Jul 27, 2026
CSPC Pharmaceutical Group has reported that its Phase III clinical trial of Ammoxetine Hydrochloride Enteric-coated Tablets, designated HA1406, for the treatment of depression met its primary efficacy endpoint with statistically and clinically mea...
CSPC Wins Priority Review for Albumin-Bound Sirolimus as Potential New Standard in Rare Tumour Care
Jul 27, 2026
CSPC Pharmaceutical Group has announced that its independently developed Sirolimus for Injection (Albumin-Bound) has had its new drug application accepted by China’s National Medical Products Administration and granted inclusion in the Break...
CSPC Sees Profit Surge on AstraZeneca Deal and Solid Drug Sales
Jul 27, 2026
CSPC Pharmaceutical Group has issued a positive profit alert for the six months ended 30 June 2026, projecting consolidated profit attributable to shareholders of between RMB5.9 billion and RMB6.2 billion, up sharply from about RMB2.55 billion a y...
CSPC Innovation Forecasts First-Half Profit on Biotech R&D Progress
Jul 27, 2026
CSPC Innovation Pharmaceutical, a Shenzhen-listed subsidiary of CSPC Pharmaceutical Group, expects to swing from a loss to a profit for the first half of 2026. Management cautioned that these unaudited figures apply only to the subsidiary, urging ...
CSPC Wins China Approval for Long-Acting Schizophrenia Injection
Jul 24, 2026
CSPC Pharmaceutical Group has received marketing approval in mainland China for its independently developed Paliperidone Palmitate Injection, a second-generation long-acting antipsychotic indicated for both acute and maintenance treatment of schiz...
CSPC Advances HPV mRNA Vaccine SYS6026 to Phase II Trial in China
Jul 22, 2026
CSPC Pharmaceutical Group has officially launched a Phase II clinical trial in China for SYS6026 Injection, a therapeutic mRNA vaccine targeting HPV types 16 and 18 in patients with cervical high-grade squamous intraepithelial lesions. The multice...
CSPC’s HER2-Targeted Breast Cancer Drug NDA Accepted by China’s NMPA
Jul 17, 2026
CSPC Pharmaceutical Group has had its new drug application for Trastuzumab Envedotin Injection accepted by China’s National Medical Products Administration, marking a key milestone in its oncology pipeline. The Class 1 therapeutic biological...
CSPC Advances B7-H3 Antibody-Drug Conjugate into Phase III Ovarian Cancer Trial in China
Jul 16, 2026
CSPC Pharmaceutical Group has initiated a randomized, multicenter Phase III clinical trial in China for SYS6043, a B7-H3-targeting antibody-drug conjugate, to treat patients with platinum-resistant advanced ovarian, primary peritoneal and fallopia...
CSPC Launches Phase II Trial for Albumin-Bound Sirolimus in Rare Vascular Cancer
Jul 16, 2026
CSPC Pharmaceutical Group has initiated a Phase II clinical trial in China for its independently developed Sirolimus for Injection (Albumin-Bound), a modified Class 2.2 chemical drug designed as a highly selective mTOR inhibitor with strong immuno...
CSPC Wins Breakthrough Status in China for New First-Line HER2 Breast Cancer Regimen
Jul 14, 2026
CSPC Pharmaceutical Group said its independently developed Docetaxel for Injection (Albumin-bound) and co-developed HER2 bispecific antibody Anbenitamab have received Breakthrough Therapy Designation from China’s National Medical Products Ad...
CSPC Receives US$25 Million R&D Milestone Payment from AstraZeneca
Jul 10, 2026
CSPC Pharmaceutical Group has received a US$25 million research and development milestone payment from AstraZeneca under their strategic collaboration and license agreement for long-acting peptide medicines. The payment, following an earlier upfro...
CSPC Launches Phase II Trial of Novel Hyperlipidaemia Drug in China
Jul 7, 2026
CSPC Pharmaceutical Group has initiated a Phase II clinical trial in China for SYH2070 Injection, an independently developed GalNAc-conjugated siRNA therapy for mixed hyperlipidaemia. The drug targets ANGPTL3 mRNA in hepatocytes to sustainably low...
CSPC launches Phase I trial in China for novel KAT6 inhibitor cancer drug
Jul 2, 2026
CSPC Pharmaceutical Group has officially started a Phase I clinical trial in China for SYH2095 tablets, a Class 1 innovative new chemical entity co-developed with Hangzhou Innogate Pharma, targeting advanced malignant tumours as a monotherapy and ...
CSPC Wins China Trial Nod for First Recombinant Herpes Zoster Vaccine
Jul 2, 2026
CSPC Pharmaceutical Group has secured approval from China’s National Medical Products Administration to begin clinical trials for its Recombinant Herpes Zoster Vaccine (SYS6052), targeting adults aged 50 and above. The vaccine combines a var...
CSPC Wins China Nod for First-Evaluated Iron Sucrose Injection
Jul 2, 2026
CSPC Pharmaceutical Group has obtained marketing approval in China for its Iron Sucrose Injection, an intravenous polysaccharide-iron complex indicated for patients with iron deficiency anaemia who do not respond well to oral iron therapies and re...
CSPC’s ADC SYS6043 Wins Breakthrough Therapy Status in China for Hard-to-Treat Ovarian Cancer
Jul 2, 2026
CSPC Pharmaceutical Group announced that its humanised antibody-drug conjugate SYS6043, targeting B7-H3, has received Breakthrough Therapy Designation in China for use as a monotherapy in platinum-resistant ovarian cancer, primary peritoneal carci...
CSPC Strikes AstraZeneca siRNA Alliance Worth Up to US$1.77 Billion
Jul 2, 2026
CSPC Pharmaceutical Group has entered into a strategic collaboration, option and license agreement with AstraZeneca to develop novel siRNA-based small nucleic acid drug candidates for renal diseases across multiple indications, using CSPC’s ...
CSPC launches Phase III trial of novel lung cancer adjuvant combo in China
Jun 30, 2026
CSPC Pharmaceutical Group has initiated a randomized, controlled Phase III clinical trial in China to test its antibody-drug conjugate SYS 6010 combined with the PD-1 monoclonal antibody Enlonstobart as adjuvant therapy for patients with completel...
CSPC Pharmaceutical Boosts Share Award Reserves With New On-Market Purchase
Jun 26, 2026
CSPC Pharmaceutical Group has announced that the trustee of its 2026 Restricted Share Award Scheme purchased 4.4 million shares on the market on 26 June 2026, representing about 0.04% of its issued share capital, at an average price of roughly HK$...
CSPC Launches Phase III Trial of SYS6010 Combo for Advanced Lung Cancer in China
Jun 26, 2026
CSPC Pharmaceutical Group has initiated a Phase III clinical trial in China to evaluate its antibody-drug conjugate SYS6010 in combination with the PD-1 inhibitor enlonstobart for the treatment of driver gene-negative, PD-L1-positive locally advan...
CSPC Expands Equity Incentive Pool With New Share Purchases for 2026 Award Scheme
Jun 25, 2026
CSPC Pharmaceutical Group has disclosed that the trustee of its 2026 Restricted Share Award Scheme purchased 5,950,000 shares on the open market on 25 June 2026, representing about 0.05% of its issued share capital, at an average price of roughly ...
CSPC Pharmaceutical Expands On-Market Buybacks for 2026 Share Award Scheme
Jun 23, 2026
CSPC Pharmaceutical Group has disclosed that the trustee of its 2026 Restricted Share Award Scheme purchased 2.9 million shares on the open market, representing about 0.03% of its issued share capital, at an average price of roughly HK$6.84 per sh...
CSPC Pharmaceutical Expands On-Market Purchases for 2026 Share Award Scheme
Jun 22, 2026
CSPC Pharmaceutical Group has announced that the trustee of its 2026 Restricted Share Award Scheme purchased 5.8 million shares on the market, representing about 0.05% of its issued share capital, at an average price of roughly HK$6.77 per share. ...
CSPC Innovation Renews H-Share Listing Bid in Hong Kong
Jun 22, 2026
CSPC Pharmaceutical Group has announced that its subsidiary, CSPC Innovation Pharmaceutical, has submitted a renewed H-share listing application to the Hong Kong Stock Exchange after the lapse of its previous attempt. The company expects CSPC Inno...
CSPC Wins U.S. FDA Nod for Trials of Long-Acting Octreotide Injection
Jun 18, 2026
CSPC Pharmaceutical Group has received approval from the U.S. Food and Drug Administration to conduct clinical trials in the U.S. for its Octreotide Long-acting Injection (SYHX2008), a once-monthly formulation designed for first-line treatment of ...
CSPC’s Secukinumab Biosimilar Application Accepted by China’s NMPA
Jun 18, 2026
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted the marketing authorisation application for its Secukinumab Injection biosimilar, developed by subsidiary CSPC Megalith Biopharmaceutical....
CSPC’s Efmedaglutide Alfa Wins Second NMPA Review for Type 2 Diabetes
Jun 18, 2026
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted a second marketing authorization application for its once-weekly Efmedaglutide Alfa (Shanmeining) injection, this time for glycaemic contr...
CSPC Pharmaceutical Trustee Buys Shares for 2026 Award Scheme
Jun 17, 2026
CSPC Pharmaceutical Group has disclosed that the trustee of its 2026 Restricted Share Award Scheme bought 2,870,000 shares on the open market on 17 June 2026, representing about 0.02% of its issued share capital, at an average price of roughly HK$...
CSPC Pharmaceutical Expands On-Market Buybacks for 2026 Share Award Scheme
Jun 16, 2026
CSPC Pharmaceutical Group has disclosed that, under its 2026 Restricted Share Award Scheme, a trustee purchased 2.8 million shares on the market on 16 June 2026 to hold in trust for selected participants. The purchase, representing about 0.02% of ...
CSPC Wins NMPA Review Nod for Novel Hypertension Combo Pill
Jun 16, 2026
CSPC Pharmaceutical Group has had its marketing authorization application accepted by China’s National Medical Products Administration for SYH9056, a single-pill combination of valsartan and levamlodipine maleate for treating mild-to-moderat...
CSPC Wins China Approval for First Quick-Dissolving Albumin-Bound Paclitaxel
Jun 15, 2026
CSPC Pharmaceutical Group has secured marketing approval in China for its Paclitaxel for Injection (Albumin-Bound) (II), a 100mg, quick-dissolving, albumin-bound paclitaxel nano-formulation for metastatic breast cancer that is claimed to be the fi...
CSPC’s Anbenitamab Combo Hits Phase III Goal in HER2-Positive Breast Cancer
Jun 10, 2026
CSPC Pharmaceutical Group announced that a Phase III clinical trial of its HER2 bispecific antibody Anbenitamab (KN026) in combination with its albumin-bound docetaxel (HB1801) for first-line treatment of HER2-positive advanced breast cancer has m...
CSPC Pharma Trustee Buys HK$15 Million in Shares for 2026 Award Scheme
Jun 9, 2026
CSPC Pharmaceutical Group has disclosed that the trustee of its 2026 Restricted Share Award Scheme purchased 2,158,000 shares on the market on 9 June 2026, representing about 0.02% of its issued share capital. The shares, bought at an average pric...
CSPC Pharmaceutical Expands 2026 Share Award Pool with On-Market Buy
Jun 8, 2026
CSPC Pharmaceutical Group has disclosed that the trustee of its 2026 Restricted Share Award Scheme purchased 5.5 million shares on the market on 8 June 2026, representing about 0.05% of its issued share capital, at an average price of roughly HK$7...
CSPC Grants 1.35 Million Restricted Shares Under 2018 Incentive Scheme
Jun 8, 2026
CSPC Pharmaceutical Group has granted 1,350,000 restricted shares at nil consideration to two employees under its 2018 Share Award Scheme, representing about 0.01% of its issued share capital. The awards, priced at a market closing value of HK$7.0...
CSPC Wins U.S. FDA Nod for Once-Monthly Semaglutide Trial
Jun 8, 2026
CSPC Pharmaceutical Group announced that its independently developed Semaglutide Long-acting Injection (SYH9017), a once-monthly GLP-1 receptor agonist, has received approval from the U.S. Food and Drug Administration to commence clinical trials. ...
CSPC Pharmaceutical Announces Retirement of Executive Director Wang Huaiyu
Jun 5, 2026
CSPC Pharmaceutical Group has announced the resignation of Executive Director Wang Huaiyu, effective 5 June 2026, upon his reaching the company’s retirement age. Wang has indicated he has no disagreement with the board and is unaware of any ...
CSPC Pharmaceutical Group Updates Board and Committee Structure
Jun 5, 2026
CSPC Pharmaceutical Group has released an updated list of its board of directors and their respective roles, underscoring the company’s governance structure and leadership responsibilities. The board includes a mix of executive and independe...
CSPC Pharmaceutical Buys 13.8 Million Shares for 2026 Award Scheme
Jun 3, 2026
CSPC Pharmaceutical Group has disclosed that, under its 2026 Restricted Share Award Scheme, a trustee purchased 13.8 million shares on the market on June 3, 2026, representing about 0.12% of the company’s issued share capital. The shares, ac...
CSPC Reports Promising Early ASCO Data for Novel B7-H3 Antibody-Drug Conjugate SYS6043
Jun 2, 2026
CSPC Pharmaceutical Group reported Phase I clinical data for SYS6043, a novel B7-H3-targeting antibody-drug conjugate featuring a topoisomerase I inhibitor payload and effector-silencing design, which was presented at the 2026 ASCO Annual Meeting....
CSPC Wins China Trial Nod for First mRNA-LNP Dual-Target CAR-T Therapy
Jun 2, 2026
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYS6063 Injection, described as the world’s first mRNA-LNP-based dual-target CAR-T cell therapy. The prod...
CSPC’s Anbenitamab Combo Tops Standard Regimen in HER2-Positive Breast Cancer Trial
Jun 1, 2026
CSPC Pharmaceutical Group reported Phase III results from the Neo-Healer trial of its HER2 bispecific antibody Anbenitamab, co-developed with Jiangsu Alphamab, combined with its albumin-bound docetaxel HB1801 as neoadjuvant therapy for early and l...
CSPC Receives US$1.2 Billion Upfront from AstraZeneca in Peptide Drug Alliance
May 29, 2026
CSPC Pharmaceutical Group has received a US$1.2 billion upfront payment from AstraZeneca under their strategic collaboration and license agreement to develop innovative long-acting peptide medicines. The funds are expected to strengthen CSPC’...
CSPC Wins China Approval for New HER2-Targeting Cancer Drug Ennituo
May 29, 2026
CSPC Pharmaceutical Group announced that Anbenitamab Injection, marketed as Ennituo and co-developed with Jiangsu Alphamab Biopharmaceuticals, has received marketing authorisation from China’s National Medical Products Administration. The re...
CSPC Pharmaceutical Wins Shareholder Backing for All AGM Resolutions
May 28, 2026
CSPC Pharmaceutical Group reported that shareholders at its annual general meeting on 28 May 2026 approved all ordinary resolutions, including receipt of the 2025 audited financial statements and a final dividend of HK15 cents per share. Investors...
CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income
May 27, 2026
CSPC Pharmaceutical Group reported first-quarter 2026 revenue of RMB6.47 billion, down 7.8% year on year, with profit attributable to shareholders falling 41.8% to RMB860 million. The sharp profit decline was mainly driven by a steep drop in licen...
CSPC Wins China Approval for Lansoprazole Capsules, Bolstering GI Portfolio
May 26, 2026
CSPC Pharmaceutical Group has received drug registration approval in China for its 30mg Lansoprazole enteric-coated capsules, a proton pump inhibitor used to treat gastric ulcers, duodenal ulcers, reflux esophagitis, Zollinger–Ellison syndro...
CSPC Wins China Approval for Ustekinumab Biosimilar Enyike, Expanding Autoimmune Portfolio
May 22, 2026
CSPC Pharmaceutical Group has received marketing authorization in China for its ustekinumab biosimilar injection Enyike, a fully human monoclonal antibody targeting IL-12 and IL-23 for the treatment of plaque psoriasis, including paediatric patien...
CSPC Wins China Approval for Targeted Budesonide Capsule in IgA Nephropathy
May 21, 2026
CSPC Pharmaceutical Group has obtained drug registration approval in China for its 4mg budesonide enteric-coated capsules, a corticosteroid-based therapy designed for adult patients with primary immunoglobulin A nephropathy at risk of disease prog...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.